Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy

Journal of Gene Medicine

Volumn 6, Issue 12, 2004, Pages 1333-1342

  Lam, John T ^a   Kanerva, Anna ^d,e   Bauerschmitz, Gerd J ^a,f   Takayama, Koichi ^a,g   Suzuki, Kaori ^a   Yamamoto, Masato ^a   Bhoola, Snehal M ^b   Liu, Bin ^a   Wang, Minghui ^a   Barnes, Mack N ^b   Alvarez, Ronald D ^b   Siegal, Gene P ^c   Curiel, David T ^a   Hemminki, Akseli ^d,e  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF HELSINKI   (Finland)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f HEINRICH HEINE UNIVERSITY   (Germany)

^g KYUSHU UNIVERSITY   (Japan)

Author keywords

Adenovirus; Gene therapy; Oncolytic virus; Ovarian cancer; Replication competent viruses; Translational research

Indexed keywords

ADENOVIRUS VECTOR; CYCLOOXYGENASE 2; ONCOLYTIC VIRUS; RETINOBLASTOMA PROTEIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA DETERMINATION; DNA REPLICATION; DRUG EFFICACY; DRUG PENETRATION; FEMALE; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VASCULARIZATION; VALIDATION PROCESS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CELL INTERACTION; VIRUS REPLICATION; WILD TYPE;

ADENOCARCINOMA; ADENOVIRIDAE; ANIMALS; CELL DEATH; DNA, VIRAL; FEMALE; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); SPHEROIDS, CELLULAR; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIRUS REPLICATION;

EID: 20044390362     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.635     Document Type: Article

References (45)

1. http://www.wiley.co.uk/genmed/clinical. Gene Therapy Clinical Trials Website. J Gene Med 2002.
2. http://www4.od.nih.gov/oba/rac/clinicaltrial.htm. Clinical trials in Human Gene Transfer. NIH OBA Human Gene Transfer Clinical Trials Database-Phase I. 2000.
3. Hemminki A, Alvarez RD. Adenoviruses in oncology: a viable option? BioDrugs 2002; 16: 77-87.
4. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-885.
5. Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 2000; 60: 6359-6366.
6. Sandmair AM, Loimas S, Puranen P, et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 2000; 11: 2197-2205.
7. Alvarez RD, Gomez-Navarro J, Wang M, et al. Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol Ther 2000; 2: 524-530.
8. Alvarez RD, Barnes MN, Gomez-Navarro J, et al. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin Cancer Res 2000; 6: 3081-3087.
9. Buller RE, Runnebaum IB, Karlan BY, et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 2002; 9: 553-566.
10. Nanda D, Vogels R, Havenga M, et al. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res 2001; 61: 8743-8750.
11. Morris JC, Wildner O. Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk. Mol Ther 2000; 1: 56-62.
12. Grill J, Lamfers ML, van Beusechem VW, et al. The organotypic multicellular spheroid is a relevant three-dimensional model to study adenovirus replication and penetration in human tumors in vitro. Mol Ther 2002; 6: 609-614.
13. Tollefson AE, Scaria A, Hermiston TW, et al. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol 1996; 70: 2296-2306.
14. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2002; 190: 279-286.
15. Denkert C, Kobel M, Pest S, et al. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 2002; 160: 893-903.
16. Yamamoto M, Davydova J, Wang M, et al. Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology 2003; 125: 1203-1218.
17. Kanerva A, Bauerschmitz GJ, Yamamoto M, et al. A cyclooxygenase-2 promoter based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma. Gene Ther 2004; 11: 552-559.
18. Yamamoto M, Alemany R, Adachi Y, et al. Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. Mol Ther 2001; 3: 385-394.
19. Takayama K, Reynolds PN, Adachi Y, et al. Conditionally replicative adenovirus, AdVEGFE1, has a possibility for universal application in various cancer treatments. Mol Ther 2002; 5: S268 (Abstr. 821).
20. Rosen LS. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 2002; 9: 36-44.
21. Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000; 19: 2-12.
22. Suzuki K, Fueyo J, Krasnykh V, et al. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 2001; 7: 120-126.
23. Bauerschmitz GJ, Lam JT, Kanerva A, et al. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res 2002; 62: 1266-1270.
24. Kanerva A, Zinn KR, Chaudhuri TR, et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 2003; 8: 449-458.
25. Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672-1677.
26. Yaginuma Y, Hayashi H, Kawai K, et al. Analysis of the Rb gene and cyclin-dependent kinase 4 inhibitor genes (p16INK4 and p15INK4B) in human ovarian carcinoma cell lines. Exp Cell Res 1997; 233: 233-239.
27. Niederacher D, Yan HY, An HX, et al. CDKN2A gene inactivation in epithelial sporadic ovarian cancer. Br J Cancer 1999; 80: 1920-1926.
28. Hemminki A, Zinn KR, Liu B, et al. In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J Natl Cancer Inst 2002; 94: 741-749.
29. Stevenson SC, Rollence M, White B, et al. Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain. J Virol 1995; 69: 2850-2857.
30. Kanerva A, Mikheeva GV, Krasnykh V, et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 2002; 8: 275-280.
31. Kanerva A, Wang M, Bauerschmitz GJ, et al. Gene transfer to ovarian cancer versus normal tissues with fiber- modified adenoviruses. Mol Ther 2002; 5: 695-704.
32. Kelly FJ, Miller CR, Buchsbaum DJ, et al. Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro. Clin Cancer Res 2000; 6: 4323-4333.
33. Vanderkwaak TJ, Wang M, Gomez-Navarro J, et al. An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches. Gynecol Oncol 1999; 74: 227-234.
34. Khuu H. Detection of coxsackie-adenovirus receptor (CAR) immunoreactivity in ovarian tumors of epithelial derivation. Appl Immunohistochem Mol Morphol 1999; 7: 266-270.
35. Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-9713.
36. Douglas JT, Kim M, Sumerel LA, et al. Efficient oncolysis by a replicating adenovirus (Ad) in vivo is critically dependent on tumor expression of primary ad receptors. Cancer Res 2001; 61: 813-817.
37. Hemminki A, Dmitriev I, Liu B, et al. Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule. Cancer Res 2001; 61: 6377-6381.
38. Barker SD, Casado E, Gomez-Navarro J, et al. An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites. Gynecol Oncol 2001; 82: 57-63.
39. Lam JT, Bauerschmitz GJ, Kanerva A, et al. Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids. Cancer Gene Ther 2003; 10: 377-387.
40. Hemminki A, Belousova N, Zinn KR, et al. An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol Ther 2001; 4: 223-231.
41. Krasnykh V, Belousova N, Korokhov N, et al. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J Virol 2001; 75: 4176-4183.
42. Suzuki K, Alemany R, Yamamoto M, et al. The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin Cancer Res 2002; 8: 3348-3359.
43. Sauthoff H, Hu J, Maca C, et al. Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. Hum Gene Ther 2003; 14: 425-433.
44. Hemminki A, Wang M, Desmond RA, et al. Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy. Hum Gene Ther 2002; 13 1505-1514.
45. Hu YL, Albanese C, Pestell RG, Jaffe RB. Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells. J Natl Cancer Inst 2003; 95: 733-740.